About: Seaweed Secondary Metabolites with Beneficial Health Effects: An Overview of Successes in In Vivo Studies and Clinical Trials

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Seaweed Secondary Metabolites with Beneficial Health Effects: An Overview of Successes in In Vivo Studies and Clinical Trials Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Seaweed Secondary Metabolites with Beneficial Health Effects: An Overview of Successes in In Vivo Studies and Clinical Trials
Creator	Pagès, Aida Pinto, Diana Rosa, Gonçalo Seca, Ana Sousa, Pedro Tavares, Wilson
Source	Medline; PMC
abstract	Macroalgae are increasingly viewed as a source of secondary metabolites with great potential for the development of new drugs. In this development, in vitro studies are only the first step in a long process, while in vivo studies and clinical trials are the most revealing stages of the true potential and limitations that a given metabolite may have as a new drug. This literature review aims to give a critical overview of the secondary metabolites that reveal the most interesting results in these two steps. Phlorotannins show great pharmaceutical potential in in vivo models and, among the several examples, the anti-dyslipidemia activity of dieckol must be highlighted because it was more effective than lovastatin in an in vivo model. The IRLIIVLMPILMA tridecapeptide that exhibits an in vivo level of activity similar to the hypotensive clinical drug captopril should still be stressed, as well as griffithsin which showed such stunning results over a variety of animal models and which will probably move onto clinical trials soon. Regarding clinical trials, studies with pure algal metabolites are scarce, limited to those carried out with kahalalide F and fucoxanthin. The majority of clinical trials currently aim to ascertain the effect of algae consumption, as extracts or fractions, on obesity and diabetes.
has issue date	2019-12-20(xsd:dateTime)
bibo:doi	10.3390/md18010008
bibo:pmid	31861879
has license	cc-by
sha1sum (hex)	b6c5840f6d745fc86f26b38cba437b620ef03167
schema:url	https://doi.org/10.3390/md18010008
resource representing a document's title	Seaweed Secondary Metabolites with Beneficial Health Effects: An Overview of Successes in In Vivo Studies and Clinical Trials
has PubMed Central identifier	PMC7024274
has PubMed identifier	31861879
schema:publication	Mar Drugs
resource representing a document's body	covid:b6c5840f6d745fc86f26b38cba437b620ef03167#body_text
is schema:about of	named entity 'DRUGS' named entity 'SUCCESSES' named entity 'KAHALALIDE F' named entity 'DEVELOPMENT' named entity 'CURRENTLY' named entity 'LOVASTATIN' named entity 'LEVEL' named entity 'CRITICAL' named entity 'SOON' named entity 'NEW DRUG' named entity 'ALGAE ' named entity 'AIMS' named entity 'SOURCE' named entity 'ACTIVITY' named entity 'DYSLIPIDEMIA' named entity 'INTERESTING' named entity 'METABOLITE' named entity 'FIRST STEP' named entity 'CLINICAL TRIALS' named entity 'STRESSED' named entity 'EFFECT' named entity 'LIMITATIONS' named entity 'IN VIVO' named entity 'POTENTIAL' named entity 'PHLOROTANNINS' named entity 'CAPTOPRIL' named entity 'PURE' named entity 'NEW' named entity 'SECONDARY METABOLITES' named entity 'STUDIES' named entity 'MAJORITY' named entity 'PROBABLY' named entity 'IN VIVO STUDIES' named entity 'IN VIVO MODEL' named entity 'ALGAL METABOLITES' named entity 'DIABETES' named entity 'AIM' named entity 'LITERATURE REVIEW' named entity 'DRUGS' named entity 'CONSUMPTION' named entity 'EXHIBITS' named entity 'HEALTH' named entity 'MODELS' named entity 'SIMILAR' named entity 'LONG' named entity 'BENEFICIAL' named entity 'IN VIVO STUDIES' named entity 'MARINE' named entity 'OVERVIEW' named entity 'TRUE' named entity 'FRACTIONS' named entity 'PROCESS' named entity 'DIECKOL' named entity 'OVERVIEW' named entity 'PHARMACEUTICAL' named entity 'EXTRACTS' named entity 'STAGES' named entity 'SECONDARY METABOLITES' named entity 'CLINICAL TRIALS' named entity 'IN VITRO STUDIES' named entity 'VARIETY' named entity 'EFFECTIVE' named entity 'MOVE' named entity 'OBESITY' named entity 'RESULTS' named entity 'LIMITED' named entity 'MACROALGAE' named entity 'SEAWEED' named entity 'EFFECTS' named entity 'STEPS' named entity 'REVEALING' named entity 'HYPOTENSIVE' named entity 'FUCOXANTHIN' named entity 'GREAT' named entity 'ANIMAL MODELS ' named entity 'GIVEN'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software